Management of convulsive status epilepticus: recent updates
1Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Encephalitis (Seoul, Korea)
|July 20, 2023
Summary
Convulsive status epilepticus (SE) is a life-threatening emergency. While benzodiazepines are first-line, fosphenytoin, valproate, and levetiracetam show similar efficacy for established SE, but refractory SE requires further research.
Area of Science:
- Neurology
- Emergency Medicine
- Pharmacology
Background:
- Convulsive status epilepticus (SE) presents a critical medical emergency.
- SE is linked to significant morbidity and mortality rates.
- Recent advancements include clinical trials and meta-analyses on SE treatments.
Purpose of the Study:
- To review current evidence on the medical treatment of convulsive SE.
- To highlight effective first-line and established SE treatments.
- To identify gaps in knowledge regarding refractory SE management.
Main Methods:
- Literature review of recent clinical trials and meta-analyses.
- Analysis of evidence for first-line treatments (benzodiazepines).
- Evaluation of second-line treatments for established SE (fosphenytoin, valproate, levetiracetam).
- Assessment of treatments for refractory SE (midazolam, ketamine).
Main Results:
- Benzodiazepines are the established first-line treatment for SE.
- Intravenous fosphenytoin, valproate, and levetiracetam demonstrate comparable efficacy for established SE.
- Evidence for treating refractory SE is limited, though intravenous midazolam and ketamine show promise.
Conclusions:
- Current treatments effectively manage established SE.
- Further research is essential to optimize the treatment of refractory SE.
- Improved management strategies are needed to reduce SE-associated morbidity and mortality.
More Related Videos
Related Concept Videos
01:30Electroconvulsive Therapy
70
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
70
01:13Seizures: Classification
424
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
424
01:24Arteries of the Lower Limbs
215
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
215
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
465
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
465
01:20Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
347
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
347